Rising PSAs after primary therapy: active or passive intervention.
Prostate cancer that has relapsed biochemically after primary therapies, such as prostatectomy or radiation, remains a therapeutic challenge in that no standard treatment option exists for this patient. These patients are often young and may be offered androgen ablation as the mainstay of treatment. Many patients do not wish to undergo a regimen that may be associated with a variety of side effects that will impact on their quality of life. Delaying hormonal treatment in this group does not compromise survival and patients may try a variety of approaches in an attempt to control rising PSAs. Therefore, these patients are an interesting subgroup for whom immunological and alternative therapies may prove to be beneficial. We review new approaches for this population of men, which result in antitumor effects with minimal toxicities.
Slovin
S F
SF
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Scher
H I
HI
D019496:Cancer Vaccines; D018752:Diet, Fat-Restricted; D015316:Genetic Therapy; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D008517:Phytotherapy; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000601:surgery* / Q000628:therapy*
D019496:Cancer Vaccines; D017430:Prostate-Specific Antigen